Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Net Margin (2016 - 2025)

Historic Net Margin for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 13591.0%.

  • Northwest Biotherapeutics' Net Margin fell 81271300.0% to 13591.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 9735.75%, marking a year-over-year decrease of 52862500.0%. This contributed to the annual value of 6164.4% for FY2024, which is 28324600.0% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Net Margin of 13591.0% as of Q3 2025, which was down 81271300.0% from 12166.41% recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Net Margin high stood at 1255.34% for Q1 2023, and its period low was 15947.57% during Q3 2022.
  • In the last 5 years, Northwest Biotherapeutics' Net Margin had a median value of 5346.33% in 2025 and averaged 6439.49%.
  • Per our database at Business Quant, Northwest Biotherapeutics' Net Margin skyrocketed by 2000000000bps in 2021 and then plummeted by -122075700bps in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Net Margin (Quarter) stood at 3740.0% in 2021, then dropped by -27bps to 4740.03% in 2022, then surged by 32bps to 3217.53% in 2023, then tumbled by -283bps to 12335.93% in 2024, then decreased by -10bps to 13591.0% in 2025.
  • Its Net Margin stands at 13591.0% for Q3 2025, versus 12166.41% for Q2 2025 and 5228.8% for Q1 2025.